Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia

Clinical Therapeutics
Elena CampioneSergio Chimenti

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder primarily characterized by the presence of the Philadelphia chromosome resulting from a reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation determines a fusion gene, bcr-abl, which encodes a constitutively active protein, tyrosine kinase, resulting in decreased apoptosis, defective adhesion, and genomic instability in transformed cells. The tyrosine kinase activity and its effects represent a potential pharmacologic target of tyrosine kinase inhibitors, such as imatinib. Flare of Kaposi's sarcoma (KS) is well described in immunosuppressed patients treated with corticosteroids and rituximab, but has not yet been reported during treatment with imatinib. We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib. A 61-year-old white male patient (weight, 90 kg) was diagnosed with CML in March 2006 at the Division of Hematology, University of Rome "Tor Vergata," Rome, Italy. He was treated with imatinib 400 mg/d, which improved his general condition with few adverse effects. After 12 months of treatment, molecular biology showed an important reduction in the peripheral blood of the fusion oncoprote...Continue Reading

References

Nov 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E AbruzzeseElena Campione
Jul 17, 2007·AIDS·Lesley A Anderson, James J Goedert
Jul 25, 2008·BMC Clinical Pathology·Liron PantanowitzBruce J Dezube

❮ Previous
Next ❯

Citations

Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josef MartzElizabeta C Popa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Mutlu DoganFikri Icli
The New England Journal of Medicine
Stefan W Krause, Ernst Holler
© 2021 Meta ULC. All rights reserved